ProCE Banner Activity

CheckMate 649 Update: Phase III Study of First-line Nivolumab + CT vs CT for Advanced Gastric/GEJ Cancer and Esophageal Adenocarcinoma

Conference Coverage
Slideset

Released: January 30, 2023

Expiration: January 29, 2024

Share

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Bristol Myers Squibb

Incyte Corporation

Seagen Inc.

Format

This program has been made available online.